What I have: a GLP-1 receptor agonist · sixteen weeks · 30 °C.
I would rather over-plan the first cycle and simplify later.
I am prepared to do the work if someone can tell me which work matters.
What is the minimum version of this that is still defensible?
Mechanically, if a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.
Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.
| Δ mass (Da) | Most likely cause | Distinguishing feature |
|---|---|---|
| +1 | Deamidation (Asn or Gln) | New peak, slightly earlier retention |
| −17 | Loss of ammonia | Often with deamidation |
| −18 | Dehydration / succinimide | pH-dependent, reversible |
| +16 | Oxidation (Met, Trp) | Earlier retention, light-related |
| −128 | Missing Gln or Lys | Deletion sequence from synthesis |
| 0 | Isomer: racemisation or scrambling | Same mass, shifted retention |
The relevant detail is that the sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.
Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.
Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.
Assume segregation is possible, and design your sampling to catch it if it exists.
edited 11 Jul 2024 by tadhg_o_riordan — updated for the 2026 guidance change
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsMore usefully, the single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.
A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.
Mechanically, if you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.
The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.
If testing multiple vials, state how many you tested and why you chose those vials.
Put another way, sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.
If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.
In practice, the statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.
The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
A certificate that reports one test result on one vial extrapolates to claim that all two hundred vials in the lot are identical, which is an assumption worth questioning.
If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.
Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.
Assume segregation is possible, and design your sampling to catch it if it exists.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.